 | |
- close
- close
|
Marketwire
Nov 19
Comment
BOTHELL, WA -- (Marketwire) -- 11/19/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International
Marketwire
Nov 18
Comment
BOTHELL, WA -- (Marketwire) -- 11/18/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming Transformational
StreetInsider.com
Nov 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AVI+BioPharma+%28AVII%29+Misses+Q3+Views+by+1c/5087172.html for the full story.
Marketwire
Nov 9
Comment
BOTHELL, WA -- (Marketwire) -- 11/09/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and nine months ending September 30, 2009. The Company will host a conference call today,
Marketwire
Nov 2
Comment
BOTHELL, WA -- (Marketwire) -- 11/02/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report third quarter 2009 financial results on Monday, Nov. 9, 2009, at 9:30 a.m. Eastern time (6:30 a.m.
Marketwire
Oct 26
Comment
BOTHELL, WA -- (Marketwire) -- 10/26/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, presented an update on preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of exon skipping AVI-4658 in patients
Marketwire
Oct 22
Comment
BOTHELL, WA -- (Marketwire) -- 10/22/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that it will present updated preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of AVI-4658 in
Marketwire
Oct 20
Comment
OXFORD, UK and BOTHELL, WA -- (Marketwire) -- 10/20/09 -- An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the
StreetInsider.com
Oct 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AVI+BioPharma+%28AVII%29+Announces+Research+of+a+PPMO+to+Prevent+Cardiomyopathy+in+DMD+Mouse+Model/5025134.html for the full story.
Marketwire
Oct 19
Comment
BOTHELL, WA -- (Marketwire) -- 10/19/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced the publication of research demonstrating the ability of a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
AVII AT A GLANCE
References
| ||||||
|
|
